{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:16:53Z","timestamp":1792527413581,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":727,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1093\/annonc\/mdx493","type":"journal-article","created":{"date-parts":[[2017,9,9]],"date-time":"2017-09-09T15:08:43Z","timestamp":1504969723000},"page":"2754-2760","source":"Crossref","is-referenced-by-count":82,"title":["A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma"],"prefix":"10.1016","volume":"28","author":[{"given":"M.H.","family":"Voss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Vogelzang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Y.","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.B.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Richey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Crowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Senderowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Figlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.B.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx493_bb0010","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx493_bb0015","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1200\/JCO.2012.45.2003","article-title":"Molecular genetics of clear-cell renal cell carcinoma","volume":"32","author":"Brugarolas","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx493_bb0020","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/annonc\/mdw241","article-title":"Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective","volume":"27","author":"Shenoy","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx493_bb0025","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","article-title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial","volume":"15","author":"Motzer","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx493_bb0030","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.nano.2014.04.003","article-title":"Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer","volume":"10","author":"Gaur","year":"2014","journal-title":"Nanomedicine. Nanomedicine"},{"key":"10.1093\/annonc\/mdx493_bb0035","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1158\/1078-0432.CCR-14-2810","article-title":"Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer","volume":"21","author":"Pham","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx493_bb0040","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1073\/pnas.1603018113","article-title":"CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing","volume":"113","author":"Clark","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1093\/annonc\/mdx493_bb0045","doi-asserted-by":"crossref","first-page":"15127","DOI":"10.1073\/pnas.1309566110","article-title":"Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle","volume":"110","author":"Eliasof","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1093\/annonc\/mdx493_bb0050","doi-asserted-by":"crossref","first-page":"42408","DOI":"10.18632\/oncotarget.9878","article-title":"Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis","volume":"7","author":"Lin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1093\/annonc\/mdx493_bb0055","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-015-3349-8","article-title":"CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer","volume":"150","author":"Conley","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdx493_bb0060","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/0008-5472.CAN-15-3435","article-title":"Preclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle-drug conjugate, in treatment of metastatic triple-negative breast cancer","volume":"76","author":"Pham","year":"2016","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdx493_bb0065","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/annonc\/mdw188","article-title":"Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial","volume":"27","author":"Keefe","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx493_bb0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx493_bb0075","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx493_bb0080","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/onc.2015.343","article-title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdx493_bb0085","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S1470-2045(15)00543-4","article-title":"Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma","volume":"17","author":"Motzer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx493_bb0090","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx493_bb0095","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/0008-5472.CAN-15-2951","article-title":"CRLX101, a nanoparticle-drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting DNA repair and HIF1alpha","volume":"77","author":"Tian","year":"2017","journal-title":"Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/11\/2754\/21556228\/mdx493.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T04:07:14Z","timestamp":1624680434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419346125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0923753419346125"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx493","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}